Delivery Order SPE2DB22D2218-SPE2DB25FR3DL
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $13,253.95 to AmerisourceBergen Drug Corp for the supply of Dupixent 200 mg/1.14 mL pens on August 1, 2025, with an ultimate completion date of August 4, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order represents a child action under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $10,317.96 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on August 15, 2025, with an ultimate completion date of August 18, 2025. This is a non-set-aside contract, indicating it was competitively awarded. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical procurement, serving military and veteran...
- The Defense Logistics Agency awarded a delivery order valued at $14,056.97 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen (2 ml formulation) on August 13, 2025, with an ultimate completion date of August 14, 2025. This is a firm fixed-price, non-set-aside contract performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99...
- The Defense Logistics Agency awarded a $17,619.85 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 23, 2025, with completion scheduled for July 24, 2025. This firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The work will be performed at AmerisourceBergen's corporate headquarters in...
- The Defense Logistics Agency awarded a $3,058.95 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Dupixent 300 mg/2 mL pens. This non-set-aside competitively awarded contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of performance is AmerisourceBergen's corporate office in Conshohocken,...
- The Defense Logistics Agency awarded a $10,809.15 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pens on July 30, 2025, with completion scheduled for July 31, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The contract carries no set-aside designation and will be...
- The Defense Logistics Agency awarded a $14,796.38 delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Dupixent 300 mg/2 ml pens. This is a firm fixed price, non-set-aside delivery order with an ultimate completion date of August 12, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a specialty biologic medication used to treat conditions including moderate-to-severe atopic...
- The Defense Logistics Agency awarded a delivery order valued at $12,151.38 to AmerisourceBergen Drug Corp for the supply of Dupixent (dupilumab) 300 mg/2 mL pen injectors on August 1, 2025, with an ultimate completion date of August 4, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $5,128.38 for Dupixent 300 mg/2 ml pen injectors on July 30, 2025, with completion scheduled for July 31, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $54,417.70 on August 14, 2025, for the supply of Dupixent 300 mg/2 mL pens. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of August 15, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. As a child contract action, this delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- SPE2DB22D2218Indefinite Delivery Contract
- SPE2DB22D2218-SPE2DB25FR3DLDelivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $10,447.52 for Dupixent 300 mg/2 ml pen (2 ml) on August 13, 2025, with completion targeted for August 14, 2025. This firm fixed-price, non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 pharmaceutical prime vendor agreement running through December 2026. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order supplies Dupixent, a prescription biologic medication used to treat atopic dermatitis, eosinophilic esophagitis, and asthma, to support federal military and veteran healthcare systems. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, maintains extensive capabilities across the Defense Health Agency supply chain and has demonstrated consistent competitiveness in open federal procurement processes. The pharmaceutical prime vendor framework enables flexible, ongoing access to a comprehensive range of brand-name and generic medications to meet military healthcare needs globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.4k | 8/13/25 |